Products/Services Used | Details | Operation |
---|---|---|
Monoclonal Antibody Services> | The following primary antibodies were used: rabbit polyclonal anti-Sirt1 (1:800; Sigma), anti-cleaved caspase-3 (1:1000; Cell Signaling Technology, Danvers, MA), anti-nitrotyrosine (1:1000; Santa Cruz), anti-AT1R (1:500; Millipore), anti-AT2R (1:500; Millipore), anti-NF-κ B (p65) (1:5000; Enzo Life Science, Farmingdale, NY, USA), anti-acetyl (K310)-NF-kB p65 (1:1000; Abcam, Cambridge, MA), anti-phospho (Ser32)-Iκ Bα (1:1000; Cell 1 0 Signaling), anti-connective tissue growth factor (CTGF; 1:1000; Peprotech, Rocky Hill, NJ, USA), hamster mono- clonal anti-monocyte chemotactic protein 1 (MCP-1; 1:500; Abcam), mouse monoclonal anti-fibronectin (1:400; Abcam), anti-GAPDH (1:2000; GenScript, Piscataway, NJ, USA), and anti-proliferating cell nuclear antigen (PCNA, 1:1000; GeneTex Inc. | Get A Quote |
Activation of sirtuin 1 (Sirt1) attenuates unilateral ureteral obstruction (UUO)-induced inflammation and fibrosis, suggesting that Sirt1 may prevent tubulointerstitial fibrosis. In this study, we explored changes in the expression of Sirt1 in the kidneys of UUO-treated rats and evaluated the effects of Sirt1 activation or inhibition on renal pathology and mediators of UUO pathogenesis, especially angiotensin II and nuclear factor (NF)-κB, in rats and rat renal fibroblasts. Sirt1 expression increased in the obstructed kidney but not in the contralateral kidney and was mainly detected in tubulointerstitial cells. Resveratrol, a Sirt1 activator, decreased UUO-induced inflammation and fibrosis, while sirtinol, a ... More